Compare Ascendis Pharma A/S (ASND) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Cisco Systems Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Cisco Systems Inc trades at $120.93 (market cap $478.14B). The key difference: Cisco Systems Inc is far larger — about 27× Ascendis Pharma A/S's market cap, and Cisco Systems Inc pays a 1.38% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CSCO | |
|---|---|---|
Market Cap | $17.74B | $478.14B |
Sector | Health | Technology |
52-Week High | $277.18 | $130.00 |
52-Week Low | $163.32 | $66.20 |
Enterprise Value | $18.11B | $492.80B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Cisco Systems (CSCO) trades at $121.31, up 2.54% with a bullish technical signal. Recent earnings beats and strong AI cybersecurity partnerships drive momentum. The stock shows solid fundamentals with $56.65B revenue and 19.69% net margin, though valuation ratios like P/E of 40.44 appear elevated. Positive analyst sentiment includes a $130.38 consensus target.
Outlook remains positive with AI-driven growth opportunities, but risks include competitive pressures and high debt levels. The stock offers steady dividends and institutional support, yet investors should monitor execution on AI initiatives and macroeconomic headwinds that could impact networking demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
